SPRAVATO® (esketamine) is the first and only NMDA receptor antagonist approved for 2 subtypes of MDD in adult patients1
SPRAVATO® hypothesized mechanism of action (MOA)
TRD=treatment-resistant depression in adults.
MDSI=depressive symptoms in adults with MDD with acute suicidal ideation or behavior.
TEAE=treatment-emergent adverse effect.
UNMET NEED IN TRD
Even after multiple treatment steps, patients with TRD may continue to experience symptoms of MDD including2*:
• Depressed mood
• Loss of interest or pleasure
• Change in sleep, appetite, or weight
• Diminished concentration
• Feelings of worthlessness and guilt
• Psychomotor agitation or retardation
• Suicidal ideation
• Fatigue or loss of energy
In the STAR*D trial3
• About one-third of patients with MDD did not respond to ≥2 oral ADs and may be considered to have TRD
• By the third line of oral therapy, remission rates dropped below 15%
SPRAVATO® clinical program overview
Studied in more than 1700 adult patients with treatment-resistant depression across all studies1
BASELINE PATIENT CHARACTERISTICS
DID NOT RESPOND TO ≥2 and ≤5 ORAL ANTIDEPRESSANTS (ADs)
• Adults with major depressive disorder (MDD) who had not responded adequately in the current depressive episode to ≥2 and ≤5 different ADs of adequate dose and duration1,4
MODERATELY TO SEVERELY DEPRESSED
• Patients included those with moderate to severe depression, based on MADRS scores1
COMPARED TO PLACEBO NASAL SPRAY + ORAL AD1
MADRS=Montgomery-Åsberg Depression Rating Scale.
*DSM-5 criteria for major depressive disorder.
Meet 3 adult patients with TRD who may be appropriate for SPRAVATO® therapy*
SPRAVATO® therapy for appropriate adult patients with TRD should only begin after a full evaluation and discussion with a healthcare provider.
*Not actual patients.
To hear stories from real patients with TRD who were treated with SPRAVATO® visit www.spravato.com/trd/patient-stories.
1. SPRAVATO® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. July 2020.
2. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry. 2010:1-152.
3. Rush AJ, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
4. Popova V, et al. Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study [published online May 21, 2019]. Am J Psychiatry. 2019;176(6):428-438. doi: 10.1176/appi.ajp.2019.19020172